BEBT-503
BEBT-503 is a potent and well-balanced pan-PPAR agonist, designed mainly for diabetes management in patients with metabolically dysfunction-associated fatty liver disease (MAFLD). Preclinical trials in a CDAHFD mouse model of diabetes with MAFLD indicated that BEBT-503 lowers baseline blood glucose, enhances glucose tolerance, and notably, does not cause weight gain. Phase I clinical trials in healthy individuals have been completed in Australia, revealing an excellent safety profile and good oral bioavailability. Phase Ib/II trials are underway for patients with diabetes, MAFLD, and primary biliary cholangitis.
Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号